Nalbuphine for Opioid-Induced Urine Retention

Ibrahim, Abdisamad; Obaidi, Zainab; Ruan, Gordon; Adaramola, Dorcas; Onguti, Sharon

doi:10.7326/l18-0387

Cited by 4 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Micturition disorders during opioid use are due to their effects on parasympathetic innervation of the bladder through µ- and 𝛿-opioid receptors, but not through the ĸ-opioid receptor; therefore, the unique receptor activity of nalbuphine does not cause micturition disorders in patients treated with nalbuphine. In addition, there is a documented literature showing the efficacy of nalbuphine in treating µ-agonist opioid-induced urinary retention without compromising the quality of analgesia [ 23 , 24 , 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Side Effects of Nalbuphine and Morphine in the Treatment of Pain in children with Cancer: A Prospective Study

Kubica-Cielińska

Czapla

Juárez‐Vela

et al. 2022

Cancers

View full text Add to dashboard Cite

Contemporary pain management regimens in children do not include the use of the middle step of the analgesic ladder, i.e., weak opioids. The aim of this study was to analyse the comparison of side effects and the therapeutic efficacy of morphine and nalbuphine in pain management in children with cancer. We conducted an observational, prospective study and analysed medical records of patients treated at the Clinic of Paediatric Haematology and Oncology of the University Hospital in Wroclaw (Poland), who developed mucositis during treatment. The efficacy and safety of both drugs were analysed, and the efficacy of pain relief and the incidence of adverse effects characteristic of opioid drugs were compared. The cases of 96 of children treated with opioid drugs nalbuphine or morphine were analysed. Nalbuphine therapy was accompanied by a statistically significantly lower incidence of side effects such as skin pruritus, constipation, and micturition disorders compared to morphine (p < 0.05). After the discontinuation of nalbuphine, signs of withdrawal syndrome were much less frequent than after morphine (p < 0.05). In Conclusion, nalbuphine used as a pain killer in children with oncological disorder is a safe drug. It provides stable analgesia in most children. Compared to morphine, the side effects typical of opioid use are less common, and the incidence decreases over time.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Side Effects of Nalbuphine and Morphine in the Treatment of Pain in children with Cancer: A Prospective Study

Kubica-Cielińska

Czapla

Juárez‐Vela

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Simultaneously, with increased sphincter tension and bladder capacity, the bladder internal pressure cannot overcome urethral sphincter resistance, leading to urinary retention. 56 Currently, it is believed that the mechanism of urinary retention caused by opioids is mainly due to the spinal cord mechanism. In case of urinary retention, self-urination can be induced first by running water, flushing the perineum with hot water, and massaging the bladder area.…”

Section: Clinical Applicationmentioning

confidence: 99%

“…The first use of a fentanyl transdermal patch for 6 to 12 hours requires a transitional analgesic dose of opioids to go through the onset of the patch. If the patch is replaced, fentanyl is stored in the fat, and the blood concentration remains stable, so no opioid drugs for excessive analgesia are needed 55 , 56 (recommendation level II, evidence level 2A, consensus level: 100.00%). During the transitional period, there is generally no need for opioid drugs due to the residual dosage of fentanyl in the subcutaneous fat of fentanyl transdermal patches.…”

Section: Patient Educationmentioning

confidence: 99%

Guidelines for Rational Clinical Use of Fentanyl Transdermal Patch

Fu,

Han,

et al. 2024

DDDT

View full text Add to dashboard Cite

Pain is one of the most common clinical symptoms of cancer patients, seriously affecting the quality of life of patients and bringing heavy mental and economic burden to families and society. The treatment of cancer pain in China is facing numerous challenges, one of which includes the irrational usage of analgesic drugs in clinical practice. As a strong opioid analgesic, transdermal fentanyl patch has been widely used due to its convenient clinical application and obvious therapeutic effect. Several basic-level hospitals and even general hospitals in China fail to appropriate the application of drugs in clinical application due to the lack of understanding of the pharmacological characteristics and clinical application of fentanyl transdermal patch by medical staff, seriously affecting the treatment quality. Therefore, it is imperative to strengthen the rational use and management of fentanyl transdermal patches. Accordingly, the initiation by the Cancer Rehabilitation and Palliative Treatment Professional Committee of the Hubei Anti-cancer Association launched the compilation of the “Guidelines for Rational Clinical Use of Fentanyl Transdermal Patch” (from now on referred to as the “Guidelines”) in Hubei Province, China. The experts in the preparation group are experts in many disciplines, such as medicine, pharmacy, and nursing. The expert group determines the outline, prepares the required regulations, and revises it repeatedly. Moreover, these experts put forward suggestions for revision to strictly control the accuracy and scientific authenticity of the contents of the “Guide”. Finally, all experts of the preparation team certify and finalize the draft. This “Guide” prepared by experts of the Cancer Rehabilitation and Palliative Treatment Professional Committee of the Hubei Anti-cancer Association and the expert advisory group with joint efforts, aims to play a positive role in promoting the rational clinical use of fentanyl transdermal patch, reducing the mental and economic burden of patients, and ensuring medical quality and medical safety.

show abstract

Hydromorphone

2019

Reactions Weekly

View full text Add to dashboard Cite

Nalbuphine for Opioid-Induced Urine Retention

Cited by 4 publications

References 3 publications

Comparison of Side Effects of Nalbuphine and Morphine in the Treatment of Pain in children with Cancer: A Prospective Study

Comparison of Side Effects of Nalbuphine and Morphine in the Treatment of Pain in children with Cancer: A Prospective Study

Guidelines for Rational Clinical Use of Fentanyl Transdermal Patch

Hydromorphone

Contact Info

Product

Resources

About